SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.790
+0.220 (6.16%)
At close: Aug 3, 2026, 4:00 PM EDT
3.840
+0.050 (1.32%)
After-hours: Aug 3, 2026, 4:56 PM EDT
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $289.8 million as of August 3, 2026. Its market cap has increased by 1,298.61% in one year.
Market Cap
289.80M
Enterprise Value
175.58M
1-Year Change
1,298.61%
Ranking
Category
Stock Price
$3.79
ChartMarket Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $289.80M, an increase of 121.64%. That is a compound annual growth rate of 15.62%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 3, 2026 | 289.80M | 62.76% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| OmniAb | 287.05M |
| Fate Therapeutics | 285.57M |
| Fulcrum Therapeutics | 273.14M |
| Niagen Bioscience | 271.36M |
| Bicycle Therapeutics | 269.47M |
| Lineage Cell Therapeutics | 269.24M |
| Sol-Gel Technologies | 268.87M |
| Immuneering | 267.20M |